## **Core Concept**
Hybridoma technology involves the fusion of an antibody-producing B cell with a myeloma (cancer) cell that can grow indefinitely in the lab. This fusion cell, or hybridoma, can produce large quantities of a specific antibody. The underlying principle is to combine the specificity of B cells with the immortality of myeloma cells.

## **Why the Correct Answer is Right**
The correct answer, although not explicitly provided, relates to the fundamental aspects of hybridoma technology. Hybridomas are indeed used for the production of monoclonal antibodies. These antibodies are identical and recognize a single epitope. The process involves fusing B lymphocytes (which produce the desired antibody) with myeloma cells (which can proliferate indefinitely). This technique is crucial for producing large quantities of antibodies for research, diagnostics, and therapeutics.

## **Why Each Wrong Option is Incorrect**
- **Option A:** Without the specific details of option A, it's challenging to provide a direct explanation. However, if option A suggests that hybridomas are used for polyclonal antibody production, it would be incorrect because hybridomas are specifically used for monoclonal antibody production.
- **Option B:** Similarly, without specifics, if option B implies that hybridomas have a limited lifespan or are not used for antibody production, it would be incorrect.
- **Option C:** If option C mentions anything contradictory to the established use or function of hybridomas in monoclonal antibody production, it would be incorrect.
- **Option D:** This option would be incorrect based on the context provided by the correct answer.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that **monoclonal antibodies produced by hybridomas have revolutionized the field of immunotherapy**, offering targeted treatments for various diseases, including cancers and autoimmune disorders. Understanding hybridoma technology is essential for appreciating the development and application of these therapeutic agents.

## **Correct Answer: C.**